|Bid||83.03 x 1200|
|Ask||83.23 x 800|
|Day's Range||82.62 - 86.79|
|52 Week Range||28.83 - 98.70|
|Beta (3Y Monthly)||2.42|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb. 26, 2020 - Mar. 2, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||86.57|
SANTA CLARA, Calif., Dec. 04, 2019 -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the.
Novocure (NVCR) and the American Association for Cancer Research (AACR) announce today their 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research program. The program represents a joint effort to promote and support innovative research on Tumor Treating Fields to help deepen the understanding of the mechanism of action and to accelerate the development of new treatment strategies. The program includes research grants and career development awards totaling more than $2 million over the next three years.
Novocure Executive Chairman William Doyle will participate in the Evercore ISI 2019 HealthCONx Conference on December 5, 2019, in Boston.
Presentations on Tumor Treating Fields cover a broad and growing range of topics, with nearly 80 percent of presentations prepared by external authors
NovoCure (NVCR) delivered earnings and revenue surprises of 140.00% and 4.82%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
NEW YORK, NY / ACCESSWIRE / October 31, 2019 / Novocure Ltd. (NASDAQ: NVCR ) will be discussing their earnings results in their 2019 Third Quarter Earnings to be held on October 31, 2019 at 8:00 AM Eastern ...
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novocure (NVCR) today announced that results from the STELLAR trial were published in The Lancet Oncology. The STELLAR trial was a prospective, single-arm trial including 80 patients that studied the use of Tumor Treating Fields, delivered via the NovoTTF-100L System, in combination with pemetrexed plus cisplatin/carboplatin as a first-line treatment for patients with unresectable, locally advanced or metastatic malignant pleural mesothelioma (MPM). Data showed a median overall survival of 18.2 months (95 percent CI, 12.1 months-25.8 months) for patients treated with NovoTTF-100L and pemetrexed plus cisplatin or carboplatin.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Novocure announced today that it will report financial results for the third quarter 2019 on Thursday, October 31, 2019, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three and nine months ended September 30, 2019, at 8 a.m.
Zai Lab Limited (ZLAB), a Shanghai-based innovative commercial stage biopharmaceutical company, and Novocure (NVCR), a global oncology company with a proprietary platform technology called Tumor Treating Fields, today announced that the China National Medical Products Administration (NMPA) granted Innovative Medical Device Designation for Optune, a Tumor Treating Fields delivery system that uses electric fields tuned to specific frequencies to disrupt cancer cell division, inhibiting tumor growth and causing affected cancer cells to die.